The FDA’s addition of post-exposure prophylaxis for COVID-19 to the emergency use authorization for Regeneron Pharmaceuticals, Inc.’s monoclonal antibody therapy REGEN-COV (casirivimab and imdevimab) on 30 July marks the biggest advance yet for pre- and post-exposure prophylaxis strategies to manage SARS-CoV-2, which aim to reduce the chance that unvaccinated people in close contact with COVID-19 patients will become ill.
Could REGEN-COV’s New US FDA Emergency Use Authorization Revive COVID-19 Prophylaxis Pipeline?
Regeneron’s neutralizing antibody cocktail earned the first post-exposure prophylaxis EUA for COVID-19, but the new use and dosing improvements need to overcome slow uptake under the original authorization for the COVID-19 treatment and the poisoned environment left by hydroxychloroquine controversies.
